Image For Activity Cover
The Lead Episode 30: A Discussion of Return-to-Play for Elite Athletes With Genetic Heart Diseases Predisposing to Sudden Cardiac Death
Description
Jason T. Jacobson, MD, FHRS, of Westchester Med Center-New York Med College discusses Return-to-Play for Elite Athletes With Genetic Heart Diseases Predisposing to Sudden Cardiac Death with Sei Iwai, MD, FHRS, of WMC Health Network, and Rachel Lampert, MD, FHRS, of Yale University School of Medicine. This study reports on cardiac events in elite athletes with genetic heart diseases associated with sudden cardiac death that, through a shared decision making process have returned to play. This was done under the care of expert sports and genetic cardiologists. The incidence of cardiac events was low and no fatalities occurred.
Learning Objectives
  • Understand that elite athletes with genetic heart diseases with risk of sudden cardiac death do not need to give up their sport unconditionally.
  • Recognize the role of shared decision making in return to play for elite athletes after a diagnosis of a genetic heart disease associated with suidden cardiac death.
Article Authors and Podcast Contributors
Article Authors
Katherine A. Martinez, J. Martijn Bos, MD, PHD, Aaron L. Baggish, MD, Dermot M. Phelan, MD, PHD, Kathryn E. Tobert, BS, Darrel B. Newman, Erica Scherer, Bradley J. Petek, MD, Michael J. Ackerman, MD, PHD, Matthew W. Martinez, MD

Podcast Contributors
Jason T. Jacobson, MD, FHRS, of Westchester Med Center-New York Med College
Sei Iwai, MD, FHRS, of WMC Health Network
Rachel Lampert, MD, FHRS, of Yale University School of Medicine
Disclosure Policy

ACE Disclosure Policy

The Heart Rhythm Society is committed to the provision of Accredited Continuing Education (formerly known as Continuing Medical Education (CME)) that is balanced, objective, and evidence based. HRS adheres to the Standards for Integrity and Independence in Accredited Continuing Education of the Accreditation Council for Continuing Medical Education (ACCME) which require that those individuals in a position to control the content of an educational activity (including, but not limited to, planners, faculty, authors, committee members, content reviewers, editors, and staff) disclose all financial relationships with an ACCME-defined ineligible company* within the 24 months prior to the disclosure.

 

Any individual who refuses to disclose financial relationships is disqualified from participating in HRS ACE-certified activities. Owners and employees of ACCME-defined ineligible companies may have no role in the planning or implementation of ACE activities without a special written exemption from the HRS Chief Learning Officer that will be granted only in specific circumstances that meet ACCME requirements.


ACCME Definition:

*An ineligible company is one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Examples of such organizations include:

  • Advertising, marketing, or communication firms whose clients are ineligible companies
  • Bio-medical startups that have begun a governmental regulatory approval process
  • Compounding pharmacies that manufacture proprietary compounds
  • Device manufacturers or distributors
  • Diagnostic labs that sell proprietary products
  • Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
  • Manufacturers of health-related wearable products
  • Pharmaceutical companies or distributors
  • Pharmacy benefit managers
  • Reagent manufacturers or sellers

 

All relevant financial relationships have been mitigated.

Host Disclosure(s):
J. Jacobson: Honoraria/Speaking/Consulting Fee: American College of Cardiology, Zoll Medical Corporation; Research (Contracted Grants for PIs Named Investigators Only): Abbott, Phillips; Stocks (Privately Held): Atlas 5D

Contributor Disclosure(s):
S. Iwai: No relevant financial relationships with ineligible companies to disclose.

R. Lampert: Honoraria/Speaking/Consulting Fee: Medtronic; Research (Contracted Grants for PIs Named Investigators Only): MediLynx, Medtronic, Boston Scientific, Medtronic Inc.


Staff Disclosure(s) (note: HRS staff are NOT in control of educational content. Disclosures are provided solely for full transparency to the learner):
J. Glenn: No relevant financial relationships with ineligible companies to disclose. 
S. Sailor: No relevant financial relationships with ineligible companies to disclose.
Summary
Availability: On-Demand
Cost: FREE
Credit Offered:
No Credit Offered
Recommended
  Heart Rhythm Society
1325 G Street NW, Suite 500
Washington, DC 20005
P: 202-464-3400 F: 202-464-3401
E: questions@heartrhythm365.org
© Heart Rhythm Society
Privacy Policy | Linking Policy | Patient Education Disclaimer | State Nonprofit Disclosures | FAQ
 
Android App Download IOS App Download Powered By